MedTrace Logo

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

NCT05585814 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-14

No results posted yet for this study

Summary

This prospective, single-arm study aims to investigate the efficacy and safety of pembrolizumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS locally advanced rectal cancer patients

Conditions

  • Locally Advanced Colorectal Cancer

Interventions

DRUG

Capecitabine

Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 3 cycles

DRUG

Oxaliplatin

Oxaliplatin is given by intravenous infusion at 130mg / m2 on Day 1 every 3 weeks for 3cycles

DRUG

Bevacizumab

Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 3 cycles

DRUG

Pembrolizumab

Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-10-01
Completion
2028-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05585814 on ClinicalTrials.gov